Latest "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Stories

03:17 EST 29th January 2015 | BioPortfolio

Here are the most relevant search results for "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" found in our extensive news archives from over 250 global news sources.

More Information about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine for you to read. Along with our medical data and news we also list autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Clinical Trials, which are updated daily. BioPortfolio also has a large database of autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Companies for you to search.

Showing "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Articles 1–25 of 15,000+

Extremely Relevant

Neuromyelitis Optica May Be Linked With Epstein-Barr Virus

Persistent, active replication of Epstein-Barr virus might play a role in neuromyelitis optica (NMO) and also might contribute to the immunological alterations that play a role in the disorder, Japanese researchers say. Reuters Health Information

Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab

Lactoferrin suppresses the Epstein–Barr virus-induced inflammatory response by interfering with pattern recognition of TLR2 and TLR9

Clinical utility gene card for: X-linked immunodeficiency with magnesium defect, Epstein–Barr virus infection, and neoplasia (XMEN)

Epstein-Barr Viral Infections - Pipeline Review, H2 2014

Recently added to the BioPortfolio report store, Epstein-Barr Viral Infections - Pipeline Review, H2 2014 is a new report from GlobalData published on 2014-11-17. This 54-page report is available in PDF from $2000. Epstein-Barr Viral Infections - Pipeline Review, H2 2014 Summary Global Markets Direct’s, ‘Epstein-Barr Viral Infections - Pipeline Review, H2 2014’, provides an overview of the...

Cell Medica raises L50M series B

Cell therapy developer Cell Medica Ltd. (London, U.K.) raised L50 million ($78.2 million) in a series B round led by Imperial Innovations. Invesco Perpetual and Woodford Investment Management also participated.Cell Medica's CMD-003 (Cytorex EBV) is i...

Valganciclovir May Curb CMV, EBV in Living Kidney Donors

Antiviral prophylaxis with valganciclovir in living kidney donors may reduce transmission of cytomegalovirus (CMV) and Epstein-Barr virus (EBV), a pilot study suggests. Reuters Health Information

Q&A: Françoise Barré-Sinoussi

Françoise Barré-Sinoussi and Luc Montagnier were jointly awarded the 2008 Nobel prize in Physiology or Medicine for their discovery of HIV in 1983. Three decades on, Barré-Sinoussi is director of the Retroviral Infections unit at the Pasteur Insti...

Novel Epstein-Barr Virus Vaccines

Epstein-Barr Virus (EBV) is the causative agent of infectious mononucleosis and is associated with certain types of cancers, such as Hodgkin's lymphoma, Burkitt's lymphoma, gastric carcinoma, and nasopharyngeal carcinoma. There are currently no vaccines against EBV on the market and there is only supportive treatment available for EBV infection.<br /><br /> The subject techn...

Could Too Much Salt Harm MS Patients?

By Steven Reinberg HealthDay Reporter THURSDAY, Aug. 28, 2014 (HealthDay News) -- Too much salt in the diet may worsen symptoms of multiple sclerosis (MS), a new study from Argentina suggests. "Many environmental factors affect MS, such as ...

Study Shows that DNA of Latent EBV May Cause Cancer; Center for the Biology of Chronic Disease Comments on the Latest Study

DNA of the Epstein Barr Virus is linked to epithelial (surface cell) malignancies and malignant transformation (cancer), according to a study published in the Journal of Pathology on December 11, 2014. (1) CBCD reviews the study and recommends two natural EBV remedies. Rochester, NY (PRWEB) January 18, 2015 “Infected with the Epstein Barr Virus (EBV)? The Center for the Biology of Chronic Disea...

Canadian Ebola vaccine licensed to Merck

Global pharma giant Merck & Co Inc. has bought the worldwide commercial rights to NewLink Genetics Corp’s experimental Ebola virus vaccine rVSV-EBOV. The vaccine platform is based on an attenuated strain of vesicular stomatitis virus that has been modified to express an Ebola virus protein that plays an essential role in establishing virus infection. The [&hellip The post Canadian E...

The Problem with Cancer Vaccines

You can’t treat a heterogeneous disease with a homogeneous treatment. That was the takeawy message from Vaccinogen’s founder at the World Vaccines Congress Europe Vaccine Nation caught up with Michael Hanna, the founder of Vaccinogen and creator of autologous patient-specific tuumor cell vaccine OncoVAX, to discuss why ther have been so many highprofile cancer vaccine failures and [&...

[Correspondence] Is Canada patent deal obstructing Ebola vaccine development?

A decade ago, Canadian Government scientists invented a vaccine against Ebola virus (VSV-ZEBOV). That vaccine is based on a live attenuated vesicular stomatitis virus, and has several known advantages over the other vaccine candidates in clinical tri...

Zoetis gets conditional OK on pig virus vaccine

Animal health company Zoetis has received conditional approval from federal regulators for a vaccine that helps fight a virus that has killed millions of piglets since it started showing up in the United States last year.The Florham Park, New Jersey, company said Wednesday that its vaccine for the porcine epidemic diarrhea virus should be available to veterinarians and pig farmers this month. The...

Next-gen polio vaccine tackles wild virus emergency

Vaccine technology being developed at The University of Queensland could hold the key to completely eradicating polio by removing live virus from the vaccine production process.

Interview: The Problem with Cancer Vaccines

You can’t treat a heterogeneous disease with a homogeneous treatment. That was the takeawy message from Vaccinogen’s founder at the World Vaccines Congress Europe Vaccine Nation caught up with Michael Hanna, the founder of Vaccinogen and creator of autologous patient-specific tuumor cell vaccine OncoVAX, to discuss why ther have been so many highprofile cancer vaccine failures and [&...

Vaccine Shows Promise Against Mosquito-Borne Virus

THURSDAY, Aug. 14, 2014 -- An experimental vaccine to protect people from the mosquito-borne chikungunya virus has shown promise in its first human trial. "This vaccine was safe and well-tolerated, and we believe that this vaccine makes a type of...

Medical News Today: New vaccine offers protection against chikungunya virus

The chikungunya virus has made headlines in the US recently with reports of cases, but a human trial of a new vaccine shows promise in protecting against the virus.

Medical News Today: Could a new vaccine offer protection against chikungunya virus?

The chikungunya virus has made headlines in the US recently with reports of cases, but a human trial of a new vaccine shows promise in protecting against the virus.

The avian cell line AGE1.CR.pIX characterized by metabolic flux analysis

Background: In human vaccine manufacturing some pathogens such as Modified Vaccinia Virus Ankara, measles, mumps virus as well as influenza viruses are still produced on primary material derived from embryonated chicken eggs. Processes depending on p...

Relevant

HIV Vaccine on the Horizon: Researchers Design HIV Immunogens

Researchers from Duke University have Discovered a Way to Elicit an Immune Response in Individuals Infected With HIV-1, the Most Common Form of the Virus The director of the Duke Center for HIV/AIDS Vaccine Immunology and Duke Human Vaccine Institute, Dr.Barton Haynes, recently published his teams findings in the reputable scientific journal ‘Cell.’ In a […]

The Lancet: virus-like particle vaccine shows promise against chikungunya

The first human trial of a new vaccine developed using non-infectious virus-like particles (VLP) appears likely to offer protection against chikungunya virus, a mosquito-borne infection, according to a study published in The Lancet. Since its re-emer...

ViroCyt and I&L Biosystems Launch Virus Counter® 3100 at the World Vaccine Congress in Brussels

October 2, 2014 ViroCyt, LLC, the leader in rapid virus quantification, announced today that, in partnership with I&L Biosystems GmbH, it is formally launching the Virus Counter® 3100 in Europe at the World Vaccine Congress to be held October 13-15 in Brussels, Belgium. “The Virus Counter 3100 is the marquee analytical tool for quickly quantifying […] The post ViroCyt and I&L...

Inhaled Ebola vaccine may offer long-term protection from virus

(University of Texas at Austin) A potentially breathable, respiratory vaccine in development has been shown to provide long-term protection against the Ebola virus for non-human primates, as reported this week in Molecular Pharmaceutics. Results from...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks